Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GANX NASDAQ:HOOK NASDAQ:IMMX NASDAQ:IMUX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGANXGain Therapeutics$1.44-1.4%$1.74$0.89▼$3.19$43.30M0.11263,875 shs246,306 shsHOOKHOOKIPA Pharma$0.89-0.9%$1.27$0.72▼$5.66$10.79M0.93154,042 shs28,044 shsIMMXImmix Biopharma$2.65-2.6%$2.48$1.26▼$3.20$73.87M0.28211,613 shs181,085 shsIMUXImmunic$0.93-0.9%$0.83$0.56▼$2.11$89.25M1.381.07 million shs668,229 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGANXGain Therapeutics0.00%-14.79%-14.79%-30.10%+33.33%HOOKHOOKIPA Pharma0.00%-3.80%-30.04%-33.96%-84.79%IMMXImmix Biopharma0.00%-2.21%+3.72%+26.19%+28.02%IMUXImmunic0.00%-16.83%+27.78%-19.00%-34.86%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGANXGain Therapeutics2.3057 of 5 stars3.65.00.00.00.60.00.6HOOKHOOKIPA Pharma3.0544 of 5 stars3.25.00.00.00.02.50.6IMMXImmix Biopharma2.6242 of 5 stars3.53.00.00.00.63.30.6IMUXImmunic2.9693 of 5 stars3.62.00.00.03.22.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGANXGain Therapeutics 3.17Buy$8.20469.44% UpsideHOOKHOOKIPA Pharma 2.33Hold$4.50408.47% UpsideIMMXImmix Biopharma 3.00Buy$7.00164.15% UpsideIMUXImmunic 3.29Buy$7.50705.15% UpsideCurrent Analyst Ratings BreakdownLatest IMMX, HOOK, IMUX, and GANX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/3/2025GANXGain TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.006/25/2025IMUXImmunicD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.006/5/2025IMUXImmunicD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.006/4/2025IMMXImmix BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.005/29/2025IMUXImmunicD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$17.00 ➝ $10.005/23/2025IMUXImmunicB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $5.005/19/2025GANXGain TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.005/16/2025IMUXImmunicWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform(Data available from 8/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGANXGain Therapeutics$50K866.02N/AN/A$0.28 per share5.14HOOKHOOKIPA Pharma$43.95M0.25N/AN/A$4.25 per share0.21IMMXImmix BiopharmaN/AN/AN/AN/A$0.48 per shareN/AIMUXImmunicN/AN/AN/AN/A$0.20 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGANXGain Therapeutics-$20.41M-$0.86N/AN/AN/AN/A-247.55%-146.06%8/6/2025 (Estimated)HOOKHOOKIPA Pharma-$43.50M-$5.85N/AN/AN/A-785.66%-120.09%-77.14%8/6/2025 (Estimated)IMMXImmix Biopharma-$21.61M-$0.70N/AN/AN/AN/A-130.02%-86.33%8/11/2025 (Estimated)IMUXImmunic-$100.51M-$1.23N/AN/AN/AN/A-326.95%-181.34%8/6/2025 (Estimated)Latest IMMX, HOOK, IMUX, and GANX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025GANXGain Therapeutics-$0.17N/AN/AN/AN/AN/A8/14/2025Q2 2025HOOKHOOKIPA Pharma-$0.64N/AN/AN/AN/AN/A8/14/2025Q1 2025IMUXImmunic-$0.19N/AN/AN/AN/AN/A8/11/2025Q1 2025IMMXImmix Biopharma-$0.21N/AN/AN/AN/AN/A5/15/2025Q1 2025HOOKHOOKIPA Pharma-$0.61-$1.23-$0.62-$1.23$3.38 millionN/A5/15/2025Q1 2025IMUXImmunic-$0.25-$0.25N/A-$0.25N/AN/A5/14/2025Q1 2025GANXGain Therapeutics-$0.16-$0.16N/A-$0.16$0.03 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGANXGain TherapeuticsN/AN/AN/AN/AN/AHOOKHOOKIPA PharmaN/AN/AN/AN/AN/AIMMXImmix BiopharmaN/AN/AN/AN/AN/AIMUXImmunicN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGANXGain Therapeutics0.052.222.22HOOKHOOKIPA PharmaN/A3.613.61IMMXImmix BiopharmaN/A1.801.80IMUXImmunicN/A0.740.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGANXGain Therapeutics11.97%HOOKHOOKIPA Pharma63.88%IMMXImmix Biopharma11.26%IMUXImmunic51.82%Insider OwnershipCompanyInsider OwnershipGANXGain Therapeutics7.18%HOOKHOOKIPA Pharma3.30%IMMXImmix Biopharma55.40%IMUXImmunic4.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGANXGain Therapeutics2030.07 million27.91 millionOptionableHOOKHOOKIPA Pharma16012.19 million11.79 millionOptionableIMMXImmix Biopharma927.88 million12.43 millionOptionableIMUXImmunic7095.82 million91.41 millionOptionableIMMX, HOOK, IMUX, and GANX HeadlinesRecent News About These CompaniesImmunic, Inc. (NASDAQ:IMUX) Receives Consensus Recommendation of "Buy" from AnalystsJuly 31 at 4:59 AM | marketbeat.comImmunic (NASDAQ:IMUX) Shares Down 3.6% - What's Next?July 29, 2025 | americanbankingnews.comImmunic (NASDAQ:IMUX) Stock Price Down 3.6% - Time to Sell?July 29, 2025 | marketbeat.comImmunic Reports Positive Long-Term Safety, Tolerability Data for Vidofludimus Calcium in MS TrialJuly 25, 2025 | msn.comImmunic board authorizes up to 35 million stock ... - Investing.comJuly 13, 2025 | investing.comImmunic, Inc. (IMUX) Latest Stock News & Headlines - Yahoo FinanceJuly 9, 2025 | ca.finance.yahoo.comImmunic, Inc. (NASDAQ:IMUX) Given Consensus Rating of "Buy" by BrokeragesJuly 6, 2025 | marketbeat.comImmunic CEO discusses Phase 2 multiple sclerosis study success - ICYMIJune 28, 2025 | proactiveinvestors.comImmunic reveals long-term data supporting potential of MS drug vidofludimus calciumJune 24, 2025 | proactiveinvestors.comImmunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple SclerosisJune 24, 2025 | prnewswire.comImmunic showcases MS drug data at BIO International Convention in Boston - ICYMIJune 21, 2025 | proactiveinvestors.comImmunic, Inc. (NASDAQ:IMUX) Chairman Duane Nash Purchases 20,000 SharesJune 17, 2025 | insidertrades.comImmunic Post-Readout: Reiterating Strong Buy As Big Drop Appears UnwarrantedJune 9, 2025 | seekingalpha.comImmunic completes Phase 3 multiple sclerosis trial enrollment - ICYMIJune 7, 2025 | proactiveinvestors.comImmunic completes patient enrollment in Phase 3 relapsing multiple sclerosis trialsJune 5, 2025 | proactiveinvestors.comImmunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MSJune 5, 2025 | prnewswire.comImmunic raises $65M in public offering to fund clinical trialsJune 3, 2025 | proactiveinvestors.comImmunic raises $65M in public offering to fund clinical trialsJune 3, 2025 | proactiveinvestors.comImmunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public OfferingJune 3, 2025 | prnewswire.comImmunic to Participate in Investor, Scientific and Industry Conferences in JuneJune 2, 2025 | prnewswire.comImmunic announces public offering of warrants to fund trialsMay 30, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMMX, HOOK, IMUX, and GANX Company DescriptionsGain Therapeutics NASDAQ:GANX$1.44 -0.02 (-1.37%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.47 +0.03 (+2.36%) As of 08/1/2025 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.HOOKIPA Pharma NASDAQ:HOOK$0.88 -0.01 (-0.90%) Closing price 08/1/2025 03:55 PM EasternExtended Trading$0.88 0.00 (-0.45%) As of 08/1/2025 07:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.Immix Biopharma NASDAQ:IMMX$2.65 -0.07 (-2.57%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.64 0.00 (-0.19%) As of 08/1/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.Immunic NASDAQ:IMUX$0.93 -0.01 (-0.91%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$0.94 +0.01 (+0.81%) As of 08/1/2025 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
